WallStreetZen

NASDAQ: GILD
Gilead Sciences Inc Earnings & Revenue

GILD past earnings growth

How has GILD's earnings growth performed historically?
Company
-97.64%
Industry
10.75%
Market
38.16%
GILD's earnings have grown slower (-61.85% per year) than the US Drug Manufacturers - General industry average (2.47%)
Performance
GILD's earnings have grown slower (-61.85% per year) than the US market average (19.7%)
Performance
GILD's earnings growth is slowing down - its growth over the last year (-97.64%) is below its 5-year compound annual rate (-61.85%)
Performance

GILD past revenue growth

How has GILD's revenue growth performed historically?
Company
9.98%
Industry
11.94%
Market
20.21%
GILD's revenue has grown slower (-5.43% per year) than the US Drug Manufacturers - General industry average (6.13%)
Performance
GILD's revenue has grown slower (-5.43% per year) than the US market average (18.53%)
Performance
GILD's revenue growth is accelerating - its growth over the last year (9.98%) is above its 5-year compound annual rate (-5.43%)
Performance

GILD earnings and revenue history

Current Revenue
$24.7B
Current Earnings
$123.0M
Current Profit Margin
0.5%
GILD's has not demonstrated consistent long-term earnings growth over the past 10 years (-94.08%)
Performance

GILD Return on equity

Current Company
0.6%
Current Industry
35.6%
Current Market
49.8%
GILD's Return on Equity (0.6%) shows a company that is not efficient at transforming shareholder equity into returns
Performance

GILD Return on assets

Current Company
0.2%
Current Industry
6.9%
Current Market
5.4%
GILD is generating lower Return on Assets (0.2%) than the US Drug Manufacturers - General industry average (6.85%)
Performance

GILD Return on capital employed

Current Company
4.71%
Current Industry
11.1%
GILD's ability to generate Return on Capital (4.71%) has decreased compared to 3 years ago (24.95%)
Performance

GILD earnings dates

Next earnings date
Apr 28, 2021

Gilead Sciences Earnings & Revenue FAQ

What were GILD's earnings last quarter?

On Feb 02, 2021, Gilead Sciences (NASDAQ: GILD) reported Q4 2020 earnings per share (EPS) of $1.24, up 41.51% year over year. Total Gilead Sciences earnings for the quarter were $1.55 billion. In the same quarter last year, Gilead Sciences's earnings per share (EPS) was $2.12.

What was GILD's earnings growth in the past year?

As of Q2 2021, Gilead Sciences's earnings has grown -97.64% year over year. This is 108.4 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 10.75%. Gilead Sciences's earnings in the past year totalled $123.00 million.

What is GILD's earnings date?

Gilead Sciences's earnings date is Apr 28, 2021. Add GILD to your watchlist to be reminded of GILD's next earnings announcement.

What was GILD's revenue last quarter?

On Feb 02, 2021, Gilead Sciences (NASDAQ: GILD) reported Q4 2020 revenue of $7.42 billion up 26.23% year over year. In the same quarter last year, Gilead Sciences's revenue was $5.88 billion.

What was GILD's revenue growth in the past year?

As of Q2 2021, Gilead Sciences's revenue has grown 9.98% year over year. This is 1.96 percentage points lower than the US Drug Manufacturers - General industry revenue growth rate of 11.94%. Gilead Sciences's revenue in the past year totalled $24.69 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.